drugset / Trial / NCT06068530
Mass Vaccine and Drug Administration, Bangladesh
RandomizedParallel-groupOpen-labelPrevention
Summary
This is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass vaccinations and drug administrations versus the current standard of care.
Timeline
- Start
- 2025-02-15
- Primary completion
- 2028-02-01
- Completion
- 2028-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ARTENIMOL | Small molecule | 2 mg/kg | — |
| Comparator | ARTENIMOL | Small molecule | 10 mg/kg | — |
| Comparator | Matrix-M1 Adjuvant | Other / unclassified | 5 ug | — |
| Comparator | Matrix-M1 Adjuvant | Other / unclassified | 10 ug | — |
| Comparator | Primaquine | Small molecule | 0.25 mg/kg | — |
| Comparator | piperaquine | Small molecule | 16 mg/kg | — |
| Comparator | piperaquine | Small molecule | 26 mg/kg | — |